Shows
Derms and ConditionsTwo Valuable Perspectives from Two Brilliant Dermatologists: Expanding the Value of Topical PDE4 InhibitionIn this episode of Tea with Dr D, host James Q. Del Rosso, DO, is joined by Christopher Bunick, MD, PhD, and later Lisa Swanson, MD, for a deep look at phosphodiesterase-4 (PDE4) inhibition in dermatology, with a special focus on topical roflumilast.
Dr Bunick opens with a primer on the science of PDE4, an enzyme that degrades cyclic AMP (cAMP), an intracellular messenger that regulates anti-inflammatory pathways. In conditions such as atopic dermatitis (AD) and psoriasis, overactive PDE4 leads to reduced cAMP and amplified inflammation. By “gumming up” PDE4, roflumilast restores a more balanced, anti-inflammatory state.
H...
2025-11-1354 min
Learn Skin with Dr. Raja and Dr. HadarEpisode 218: Breaking Down AD: Cytokines, Skin Barriers, and Better CareLooking to go molecule deep in atopic dermatitis? We've got just the expert. This week, we're joined by Dr. Christopher Bunick as he brings structural biology into the atopic dermatitis discourse. Listen in as he discusses cytokines, itch, and the new definition of "skin clearance." Each Thursday, join Dr. Raja and Dr. Hadar, board-certified dermatologists, as they share the latest evidence-based research in integrative dermatology. For access to CE/CME courses, become a member at LearnSkin.com. Christopher Bunick, MD PhD is an Associate Professor of Dermatology at Yale School of Medicine in the Department of Dermatology. He specializes in g...
2025-09-0336 min
The Journal of Clinical and Aesthetic DermatologyExtended-cut Podcast— Naiem Issa, MD, PhD, and Christopher Bunick, MD, PhD: Mechanisms of Dupilumab-associated Arthralgia in Patients with Atopic DermatitisSend us a textIn this extended cut from JCAD’s recent Journal Review video series, Drs. Issa and Bunick dive into the possible mechanistic explanations behind arthralgia associated with dupilumab, which was detailed in a case series by Drs. Issa and Bunick and their colleagues in the May issue of The Journal of Clinical and Aesthetic Dermatology.
2025-05-2724 min
The Journal of Clinical and Aesthetic DermatologyNaiem Issa, MD, PhD, and Christopher Bunick, MD, PhD: Mechanisms of Dupilumab-associated Arthralgia in Patients with Atopic DermatitisDrs. Issa and Bunick dive into the possible mechanistic explanations behind arthralgia associated with dupilumab, which was detailed in a case series by Drs. Issa and Bunick and their colleagues in the May issue of The Journal of Clinical and Aesthetic Dermatology.
2025-05-2724 minThe Journal of Clinical and Aesthetic DermatologyNaiem Issa, MD, PhD, and Christopher Bunick, MD, PhD: JAK Inhibitors Reducing Dupilumab-associated Arthralgia in Patients with AD
2025-05-2308 min
DermConsultAtopic Dermatitis: Implementing the Latest Treatment Guidelines into Practice
Host: Raj Chovatiya, MD, PhD
Guest: Christopher Bunick, MD, PhD, FAAD
The American Academy of Dermatology recently updated the treatment guidelines for atopic dermatitis to include the latest systemic therapies, like biologics and JAK inhibitors. Since these new standards of care could offer improved outcomes for our patients with atopic dermatitis, Dr. Raj Chovatiya speaks with Dr. Christopher Bunick about what the new guidelines recommend and how we can incorporate them into clinical practice. Dr. Bunick is an Associate Professor of Dermatology at the Yale School of Medicine.
2025-01-0800 min
DermDocsAchieving More: How and When to Switch Systemic Therapies in Atopic Dermatitis?This is the sixth episode of our ongoing "Program on JAK Inhibitors for Atopic Dermatitis" series, hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, "Achieving More: How and When to Switch Systemic Therapies in Atopic Dermatitis?", featuring Beth Sweney, PA-C discusses the following topics: Challenges in achieving treatment targets in AD Therapeutic inertia and clinical implications of inadequate response Comparative clinical data evaluating upadacitinib and dupilumab for treatment of AD Transitioning to systemic therapies from topical agents, immunosuppressives, and biologic therapies
2024-11-1356 min
DermDocsChronic Hand Eczema: All Hands on DeckThis podcast episode, sponsored by Leo Pharma, features LiVDerm faculty and esteemed dermatologists Dr. Christopher Bunick, MD, PhD, and Dr. Jonathan Silverberg, MD, PhD, MPH. As experts in all things concerning eczema, our faculty discuss the differentiating features and disease burden in patients suffering from chronic hand eczema (CHE) and review the current guidance for treatment, including these specific topics: Differentiating CHE from atopic dermatitis of the hands, including triggers, pathophysiology, and clinical presentation Expert guidance for accurate diagnosis and work-up of CHE patients Challenges and limitations of current therapeutic offerings ...
2024-10-1847 min
DermDocsSkirting Steroids in Atopic Dermatitis: New Therapies and Expert Strategies for Long-term ControlThis is the second episode of a two-part activity on "Skirting Steroids in Atopic Dermatitis", supported by an educational grant from Arcutis Biotherapeutics, Inc., and hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, "New Therapies and Expert Strategies for Long-term Control", featuring expert dermatologist Dr. Jonathan Silverberg, MD, PhD, MPH, discusses the following topics: The pros and cons of steroid use in treating AD Targeted non-steroidal topical therapies approved by the FDA Relevant clinical efficacy and safety data for new and emerging non-steroidal topicals Recommendations for long-term symptom...
2024-09-1659 min
DermDocsChoosing the Right Path: JAK Inhibitors or Biologics for Atopic Dermatitis?This is the fifth episode of our new "Program on JAK Inhibitors for Atopic Dermatitis" series, hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, "Choosing the Right Path: JAK Inhibitors or Biologics for Atopic Dermatitis?", featuring expert dermatologist Dr. Naiem Issa, MD, PhD, discusses the following topics: Mechanistic differences between JAKi and biologics for treatment of AD Clinical data supporting the safety of JAKi in head-to-head trials compared to biologics Pearls for prescribing JAKi to AD patients Strategies for choosing JAKi vs biologics based on safety and patient...
2024-09-0557 min
DermDocsSkirting Steroids in Atopic Dermatitis: Dangers and Side Effects of Steroid Exposure in Treatment of ADThis is the first episode of a two-part activity on "Skirting Steroids in Atopic Dermatitis", supported by an educational grant from Arcutis Biotherapeutics, Inc., and hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, "Dangers and Side Effects of Steroid Exposure in Treatment of AD", featuring expert dermatologist Dr. Peter Lio, MD, discusses the following topics: Side effects of topical and oral corticosteroid exposure Pearls and gaps in current guidelines for treatment of AD Identifying topical steroid withdrawal symptoms Safety and stewardship strategies for topical steroids Future...
2024-08-1457 min
DermDocsSetting the Stage: Effective Onboarding of your AD Patients onto JAK Inhibitor TherapyThis is the fourth episode of our new "Program on JAK Inhibitors for Atopic Dermatitis" series, hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, "Setting the Stage: Effective Onboarding of your AD Patients onto JAK Inhibitor Therapy", featuring expert dermatologist Dr. Ruth Ann Vleugels, MD, MPH discusses the following topics: Identifying ideal candidates for oral JAK inhibitor therapy Steps to initiate therapy and onboard new patients How to manage side effects and maintain adherence to treatment Case examples and real-world data
2024-08-0557 min
DermDocsThe Quest for Itch-Free, Clear Skin in Atopic Dermatitis: New Practice-Informing EvidenceThis is the third episode of our new "Program on JAK Inhibitors for Atopic Dermatitis" series, hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, "The Quest for Itch-Free, Clear Skin in Atopic Dermatitis: New Practice-Informing Evidence", featuring expert dermatologist Dr. Jonathan Silverberg, MD, PhD, MPH, discusses the following topics: Overall impact of atopic dermatitis on patients' quality of life Overview of the role of various existing treatments for AD and expert guidelines Discussion of LEVEL UP clinical trial data comparing upadacitinib and dupilumab Defining treatment success and best...
2024-07-0350 min
DermDocsJAK Inhibitors in Action: Effectiveness in Atopic DermatitisThis is the second episode of our new "Program on JAK Inhibitors for Atopic Dermatitis" series, hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, "JAK Inhibitors in Action: Effectiveness in Atopic Dermatitis", featuring expert dermatologist Dr. James Song, MD, discusses the following topics: Short- and long-term efficacy and safety data for JAK inhibitor therapies New topline data from the LEVEL UP trial studying upadacitinib in comparison to dupilumab for the treatment of patients aged 12 years and older with moderate-to-severe AD Head-to-head studies and real-world evidence evaluating JAK inhibitor therapies E...
2024-05-2947 min
DermDocsThe Spectrum of Atopic Dermatitis and the Emerging Role of JAK Inhibitors This is the first episodes of a new series hosted by expert dermatologist Dr. Christopher Bunick who will be discussing the evolving role of JAK inhibitor therapies in the management of atopic dermatitis (AD). This episode, "The Spectrum of Atopic Dermatitis and the Emerging Role of JAK Inhibitors", featuring expert dermatologist Dr. John Koo, discusses the following topics: Understanding atopic dermatitis as a spectrum disorder, phenotypes and endotypes, and heterogeneity of atopic disease Summarizing JAK inhibitor therapies, including clinical safety and efficacy and mechanism of action Comparison of JAKi to biologics and traditional systemic agents, and the evolving role of...
2024-04-2448 min
The Cutaneous ConnectionMake Data-Driven Decisions For Personalized AD TreatmentChristopher Bunick, MD, PhD, associate professor of dermatology at Yale School of Medicine in New Haven, Connecticut and Dermatology Times Editorial Advisory Board Member, caught up with us at the 2024 American Academy of Dermatology Meeting to decode new atopic dermatitis treatment data and how that translates to personalized options for patients.
2024-04-0810 min
Derms and ConditionsPart 2: Special Edition on Recent Reports of Benzene Found in Benzoyl Peroxide ProductsIn this 2-part special edition of Derms and Conditions, host James Q Del Rosso, DO, sits down with David Light, cofounder and president of Valisure, and Christopher Bunick, associate professor of dermatology and translational medicine at Yale University and medical and dermatologic advisor for Valisure, to shed light on Valisure’s recent Citizen Petition to the US Food and Drug Administration regarding findings of high levels of benzene in benzoyl peroxide-containing products.In Part 1, Dr Del Rosso interviews David Light, cofounder and president of Valisure, an independent quality assurance company that aims to address a critical gap in t...
2024-03-2133 min
Derms and ConditionsPart 1: Special Edition on Recent Reports of Benzene Found in Benzoyl Peroxide ProductsIn this 2-part special edition of Derms and Conditions, host James Q Del Rosso, DO, sits down with David Light, cofounder and president of Valisure, and Christopher Bunick, associate professor of dermatology and translational medicine at Yale University and medical and dermatologic advisor for Valisure, to shed light on Valisure’s recent Citizen Petition to the US Food and Drug Administration regarding findings of high levels of benzene in benzoyl peroxide-containing products.In Part 1, Dr Del Rosso interviews David Light, cofounder and president of Valisure, an independent quality assurance company that aims to address a critical gap in t...
2024-03-2122 minThe Cutaneous ConnectionSplish, Splash: AD Management Starts in the BathThis episode recaps a discussion during a recent Masterclasses in Dermatology Atopic Dermatitis meeting. Course Director Emmy Graber, MD, MBA, moderated a faculty Q&A after sessions. She asked leading atopic dermatitis experts about bathing routine advice for patients and families. They took different ages, cultures, and more into consideration. Rebecca Smith, MD; Lawrence Eichenfield, MD; Zakiya Pressley Rice, MD; and Christopher Bunick, MD, PhD; weighed in.
2023-12-0509 min
DermDocsEczema Awareness Month with Christopher Bunick, MD, PhDn support of Eczema Awareness Month, LiVDerm sat down with one of the nation’s top experts on atopic dermatitis, Christopher G. Bunick, MD, PhD, to discuss this widespread skin condition that affects millions worldwide. Associate professor of dermatology at Yale University School of Medicine, Dr. Bunick covers emerging targeted therapies and also looks at the concerns over their safety and efficacy. He also addresses some of the gaps that persist in treatment despite these new therapies.
2023-10-2528 min
Derms and ConditionsImproving Our Understanding of How Drugs Work: Clarifying Questions with Monoclonal Antibodies and JAK Inhibitors.In Episode 59 of Derms and Conditions, our host, James Q. Del Rosso, DO, continues his conversation with Christopher Bunick, MD, PhD, an associate professor of dermatology at Yale University School of Medicine who performs specialized research on novel treatments and therapies. After discussing sarecycline for acne in part 1, the two switch gears to monoclonal antibodies. Dr Bunick begins by discussing dupilumab, an IL-4 and IL-13 blocker with significant clinical efficacy and a favorable safety profile in treating atopic dermatitis (AD). He states that in a network meta-analysis, upadacitinib and abrocitinib were shown to be more effective at t...
2023-09-0725 min
Derms and ConditionsImproving Our Understanding of How New and Established Drugs Work: Let's Start With Our Most Often Used Antibiotic ClassIn episode 57 of Derms and Conditions, our host, James Q. Del Rosso, DO, sits down with Christopher Bunick, MD, PHD, an associate professor of dermatology at Yale University School of Medicine who performs specialized dermatologic research utilizing x-ray crystallography and other novel techniques. The 2 discuss research findings surrounding new information on properties that differentiate the activity of antibiotics, with specific data on how narrow spectrum activity with sarecycline differs from the broad-spectrum tetracyclines we use in dermatology. There are new data described by Dr Bunick and his team on how the unique molecular structure of sarecycline targets Cutibacterium acnes...
2023-08-0322 min
The Cutaneous ConnectionJAK Inhibitor Safety for Treating ADIn this episode, Christopher Bunick, MD, PhD, associate professor of dermatology at the Yale School Medicine, and a Dermatology Times Editorial Advisory Board member, discusses a paper he recently co-authored, titled “JAK Inhibitor Safety Compared to Traditional Systemic Immunosuppressive Therapies,” with Stefano Daniele, PhD candidate of the Medical Scientist Training Program at the Yale School of Medicine.
2022-12-1403 min
The Dermatology Digest Podcast ExclusivesInnovations in Oral Antibiotic Therapy for AcneOral antibiotics are frequently used to treat moderate to severe acne. In the first podcast in this 3-part series, Christopher Bunick, MD, PhD, Associate Professor of Dermatology, Yale School of Medicine, New Haven, Connecticut, discusses indications, concerns, and improvements in oral antibiotic therapy for acne.
2022-11-3013 min
The Dermatology Digest Podcast ExclusivesOral Antibiotics for Acne: A ReviewOral antibiotics are frequently used to treat moderate to severe acne. In the first podcast in this 3-part series, Dr. Christopher Bunick discusses indications, concerns, and improvements in oral antibiotic therapy for acne.
2022-11-0111 min
DermDocsChristopher Bunick, MD, PhD - August 11, 2022 - The New Kids on the Block: IL-13 Inhibitors for the Treatment of Moderate-to-Severe Atopic DermatitisChristopher Bunick, MD, PhD, LiVDerm faculty and member of the SBS Planning Committee, shares key takeaways from his session at the SBS 2022 event regarding IL-13 inhibitors for treatment of AD and the underlying disease pathogenesis. With the several ongoing advances in the availability of more treatment options for managing atopic dermatitis, how can the practicing clinician best select the most appropriate treatment option that will address the underlying causes of disease progression? As with most treatment options for chronic conditions, side effects often occur. What considerations should clinicians remember when discussing treatment-related adverse events with their p...
2022-09-2005 min
The Cutaneous ConnectionBenzene Contamination UpdateIn this episode, we provide an update on a story we broke regarding benzene contamination being detected in various sunscreens and after-sun care products. Now, Johnson & Johnson has conducted its own internal testing and is recalling 5 different aerosol sunscreen products from Neutrogena and Aveeno. Listen as Christopher Bunick, MD, explains what this means for the sun protection industry and the next steps for the FDA.
2021-07-2221 minThe Cutaneous ConnectionAntibiotics for AcnePerceptions of antibiotics and potential antibiotic resistance have caused some physicians to be wary of the drug class when prescribing an acne treatment regimen. Christopher Bunick, M.D., Ph.D., clears the air around antibiotic use for acne and discusses his research of narrow-spectrum antibiotics.
2020-11-2320 min
Yale HealthcastsHow can I prevent and treat dry skin? November 2012Dr. Christopher Bunick discusses how to prevent dry skin with a three-prong approach -- bathing etiquette, moisturization and water therapy. He also specifies how to treat skin that is presenting with white flakes and an itchy rash or is inflamed. Be sure to visit our site for more information, http://yalehealth.yale.edu.
2012-12-2109 min